{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:35:44Z","timestamp":1762522544908,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PHRC-N 2018","award":["PHRCN-18-0529"],"award-info":[{"award-number":["PHRCN-18-0529"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The indication for antibiotic prophylaxis in burn patients remains highly controversial, with no consensus having been reached. The objective of antibiotic prophylaxis is to reduce the risk of postoperative local and systemic infections. Burn surgery is associated with a high incidence of bacteremia, postoperative infections, and sepsis. However, antibiotic prophylaxis exposes patients to the risk of selecting drug-resistant pathogens as well as to the adverse effects of antibiotics (i.e., <jats:italic>Clostridium difficile<\/jats:italic> colitis). The lack of data precludes any strong international recommendations regarding perioperative prophylaxis using systemic antibiotics in this setting.<\/jats:p>\n<jats:p>The goal of this project is therefore to determine whether perioperative systemic antibiotic prophylaxis can reduce the incidence of postoperative infections in burn patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>The A2B trial is a multicenter (10 centers), prospective, randomized, double-blinded, placebo-controlled study. The trial will involve the recruitment of 506 adult burn patients with a total body surface area (TBSA) burn of between 5 and 40% and requiring at least one excision-graft surgery for deep burn injury. Participants will be randomized to receive antibiotic prophylaxis (antibiotic prophylaxis group) or a placebo (control group) 30\u2009min before the incision of the first two surgeries. The primary outcome will be the occurrence of postoperative infections defined as postoperative sepsis and\/or surgical site infection and\/or graft lysis requiring a new graft within 7\u2009days after surgery. Secondary outcomes will include mortality at day 90 postrandomization, skin graft lysis requiring a new graft procedure, postoperative bacteremia (within 48\u2009h of surgery), postoperative sepsis, postoperative surgical site infection, number of hospitalizations until complete healing (&gt;\u200995% TBSA), number of hospitalization days living without antibiotic therapy at day 28 and day 90, and multiresistant bacterial colonization or infection at day 28 and day 90.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Discussion<\/jats:title>\n<jats:p>The trial aims to provide evidence on the efficacy and safety of antibiotic prophylaxis for excision-graft surgery in burn patients.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Trial registration<\/jats:title>\n<jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04292054\">NCT04292054<\/jats:ext-link>. Registered on 2 March 2020<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13063-020-04894-y","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T12:05:53Z","timestamp":1606305953000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The A2B trial, antibiotic prophylaxis for excision-graft surgery in burn patients: a multicenter randomized double-blind study"],"prefix":"10.1186","volume":"21","author":[{"name":"for the A2B trial investigators","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"D\u00e9pret","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Farny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Jeanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kada","family":"Klouche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Nouette-Gaulain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Pantet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"R\u00e9merand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Roquilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Fran\u00e7oise","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Sztajnic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Wiramus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Vicaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9788-5316","authenticated-orcid":false,"given":"Matthieu","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"4894_CR1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1046\/j.1524-475X.2002.10606.x","volume":"10","author":"AJ Singer","year":"2002","unstructured":"Singer AJ, McClain SA. Persistent wound infection delays epidermal maturation and increases scarring in thermal burns. Wound Repair Regen. 2002;10:372\u20137.","journal-title":"Wound Repair Regen"},{"key":"4894_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/00001432-200404000-00004","volume":"17","author":"R Edwards","year":"2004","unstructured":"Edwards R, Harding KG. Bacteria and wound healing. Curr Opin Infect Dis. 2004;17:91\u20136.","journal-title":"Curr Opin Infect Dis"},{"key":"4894_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1128\/CMR.19.2.403-434.2006","volume":"19","author":"D Church","year":"2006","unstructured":"Church D, Elsayed S, Reid O, Winston B, Lindsay R. Burn wound infections. Clin Microbiol Rev. 2006;19:403\u201334.","journal-title":"Clin Microbiol Rev"},{"key":"4894_CR4","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ajic.2018.09.010","volume":"47","author":"T Vauchel","year":"2019","unstructured":"Vauchel T, Pirracchio R, Chaussard M, Lafaurie M, Rouveau M, Rousseau C, et al. Impact of an Acinetobacter baumannii outbreak on kidney events in a burn unit: a targeted machine learning analysis. Am J Infect Control. 2019;47:435\u20138.","journal-title":"Am J Infect Control"},{"key":"4894_CR5","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1093\/cid\/ciw563","volume":"63","author":"M Legrand","year":"2016","unstructured":"Legrand M, Gits-Muselli M, Boutin L, Garcia-Hermoso D, Maurel V, Soussi S, et al. Detection of circulating Mucorales DNA in critically ill burn patients: preliminary report of a screening strategy for early diagnosis and treatment. Clin Infect Dis. 2016;63:1312\u20137.","journal-title":"Clin Infect Dis"},{"key":"4894_CR6","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/myc.12872","volume":"62","author":"E Dudoignon","year":"2019","unstructured":"Dudoignon E, Alanio A, Anstey J, Depret F, Coutrot M, Fratani A, et al. Outcome and potentially modifiable risk factors for candidemia in critically ill burns patients: a matched cohort study. Mycoses. 2019;62:237\u201346.","journal-title":"Mycoses"},{"key":"4894_CR7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jamcollsurg.2008.11.012","volume":"208","author":"R Gomez","year":"2009","unstructured":"Gomez R, Murray CK, Hospenthal DR, Cancio LC, Renz EM, Holcomb JB, et al. Causes of mortality by autopsy findings of combat casualties and civilian patients admitted to a burn unit. J Am Coll Surg. 2009;208:348\u201354.","journal-title":"J Am Coll Surg"},{"key":"4894_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.burns.2003.09.016","volume":"30","author":"AO Ugburo","year":"2004","unstructured":"Ugburo AO, Atoyebi OA, Oyeneyin JO, Sowemimo GOA. An evaluation of the role of systemic antibiotic prophylaxis in the control of burn wound infection at the Lagos University Teaching Hospital. Burns. 2004;30:43\u20138.","journal-title":"Burns"},{"key":"4894_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.burns.2010.06.008","volume":"37","author":"SJ Crabtree","year":"2011","unstructured":"Crabtree SJ, Robertson JL, Chung KK, Renz EM, Wolf SE, Hospenthal DR, et al. Clostridium difficile infections in patients with severe burns. Burns. 2011;37:42\u20138.","journal-title":"Burns"},{"key":"4894_CR10","doi-asserted-by":"publisher","first-page":"c241","DOI":"10.1136\/bmj.c241","volume":"340","author":"T Avni","year":"2010","unstructured":"Avni T, Levcovich A, Ad-El DD, Leibovici L, Paul M. Prophylactic antibiotics for burns patients: systematic review and meta-analysis. BMJ. 2010;340:c241.","journal-title":"BMJ"},{"key":"4894_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jhin.2017.06.015","volume":"97","author":"G Ramos","year":"2017","unstructured":"Ramos G, Cornistein W, Cerino GT, Nacif G. Systemic antimicrobial prophylaxis in burn patients: systematic review. J Hosp Infect. 2017;97:105\u201314.","journal-title":"J Hosp Infect"},{"key":"4894_CR12","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.burns.2009.10.006","volume":"37","author":"F Ravat","year":"2011","unstructured":"Ravat F, Le-Floch R, Vinsonneau C, Ainaud P, Bertin-Maghit M, Carsin H, et al. Antibiotics and the burn patient. Burns. 2011;37:16\u201326.","journal-title":"Burns"},{"key":"4894_CR13","doi-asserted-by":"crossref","unstructured":"Barajas-Nava LA, L\u00f3pez-Alcalde J, Roqu\u00e9 i Figuls M, Sol\u00e0 I, Bonfill Cosp X. Antibiotic prophylaxis for preventing burn wound infection. Cochrane Wounds Group, editor. Cochrane Database of Systematic Reviews; 2013. Available from: http:\/\/doi.wiley.com\/10.1002\/14651858.CD008738.pub2. Cited 2018 Jan 5.","DOI":"10.1002\/14651858.CD008738.pub2"},{"key":"4894_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158:200.","journal-title":"Ann Intern Med"},{"key":"4894_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801.","journal-title":"JAMA"},{"key":"4894_CR16","doi-asserted-by":"crossref","unstructured":"Azzopardi EA, Azzopardi E, Camilleri L, Villapalos J, Boyce DE, Dziewulski P, et al. Gram negative wound infection in hospitalised adult burn patients-systematic review and metanalysis-. McDowell A, editor. PLoS One. 2014;9:e95042.","DOI":"10.1371\/journal.pone.0095042"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04894-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-020-04894-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-020-04894-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T12:40:36Z","timestamp":1606308036000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04894-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["4894"],"URL":"https:\/\/doi.org\/10.1186\/s13063-020-04894-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This trial will be conducted in patients who are potentially unable to consent. Therefore, patients can be included under the emergency provisions of the law (Article L1122-1-3 of the PHC\/Order No. 2016-800 of June 16, 2016\u2014art. 2). Obviously, given the inclusion and non-inclusion criteria, the consent of patients or relatives, if present, cannot be collected at baseline. Thus, given the extreme emergency situation not allowing collecting the prior consent of the person or relative, the protocol provides that their consent is not necessary. In case of successful resuscitation, delayed consent will be asked to the patient for further participation in the study. The participant shall be informed regarding the study during his or her hospitalization as soon as his or her condition allows. Thereafter, if the patient agrees, he or she signs the delayed consent form to pursue his or her participation in the research, and a \u201cno objection to the use of his\/her data\u201d form for the possible continuation of this research will be completed.According to the law (art. L1122-2 and L1121-8 of the Public Health Code), if the patient has a legal representative (guardian designated by law), it belongs to the patient\u2019s guardian to give his or her consent for further participation in the research and the collection and exploitation of the data.The study protocol was approved by the institutional review board (IRB) of Sud Est IV on 11 December 2019 (approval number 2019-002396-34), and from the agence nationale de s\u00e9curit\u00e9 du medicament et des produits de sant\u00e9 (MEDAECNAT-2019-10-00036), it was registered as a clinical trial on 2 March 2020 (NCT03788837) and in EudraCT (No. 2019-002396-34).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"As clinical images or other clinical and personal data are not shown, consent for publication is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"ML reports consulting fees from Novartis, lecture fees from Baxter and Fresenius, and research support from Shingotec.EV declares no conflict of interest.FD received lecture fees from Sedana Medical and Biomerieux and research grant from the French Ministry of Health, European Society of Intensive Care Medicine, and Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie R\u00e9animation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"973"}}